Tevogen Bio与BARDA讨论其AI驱动的ExacTcell技术, 旨在迅速应对病毒威胁。 Tevogen Bio discusses its AI-driven ExacTcell tech with BARDA, aiming to swiftly address viral threats.

Tevogen Bio 与BARDA技术观察小组会晤,讨论其旨在迅速适应病毒威胁的ExacTcell技术。 Tevogen Bio met with the BARDA TechWatch team to discuss its ExacTcell technology, aimed at rapidly adapting to viral threats. 该技术目前正在为治疗传染病进行概念验证试验,它使用人工智能,并承诺进行可扩展的、负担得起的免疫疗法。 The technology, currently in proof-of-concept trials for treating infectious diseases, uses AI and promises scalable, affordable immunotherapy. Tevogen强调其作为医疗应对措施的潜力,并计划在与联邦实体接触时向利益攸关方提供最新情况。 Tevogen emphasized its potential as a medical countermeasure and plans to update stakeholders as it engages with federal entities.